<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869228</url>
  </required_header>
  <id_info>
    <org_study_id>GT0918-MR-3001</org_study_id>
    <nct_id>NCT04869228</nct_id>
  </id_info>
  <brief_title>A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Kintor Pharmaceutical Inc,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Kintor Pharmaceutical Inc,</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in&#xD;
      male outpatients with mild to moderate COVID-19 disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects in the experimental group will receive GT0918 (200mg oral once-daily (QD) for 14&#xD;
      consecutive days) in addition to supportive treatment. The subjects in the control group will&#xD;
      receive placebo (200mg oral once-daily (QD) for 14 consecutive days) in addition to&#xD;
      supportive treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects requiring oxygen by Day 28</measure>
    <time_frame>28days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who experience the events(such as hospitalization,Death etc.) by Day 28. (not applicable for subjects whose countries require mild to moderate COVID-19 patients to be hospitalised, such as COVID-19 patients in mainland China)</measure>
    <time_frame>28days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">724</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>GT0918 in the treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT0918 tablets : oral, 1 time / day, 2 tablets / time, after meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in the placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo : oral, 1 time / day, 2 tablets / time, after meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GT0918 tablets or placebo</intervention_name>
    <description>GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals</description>
    <arm_group_label>GT0918 in the treatment arm</arm_group_label>
    <arm_group_label>Placebo in the placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males age ≥18 years of age at the time of randomization&#xD;
&#xD;
          2. Are currently not hospitalized for acute respiratory symptoms (not applicable for&#xD;
             subjects whose countries require mild to moderate COVID-19 patients to be&#xD;
             hospitalised, such as COVID-19 patients in mainland China)&#xD;
&#xD;
          3. The subject's first positive SARS-CoV-2 viral infection test result (using an approved&#xD;
             molecular test, or other approved commercial or public health assay on any approved&#xD;
             specimen) must be ≤3 days prior to randomization&#xD;
&#xD;
          4. Subjects with adequate liver and renal function&#xD;
&#xD;
          5. Agree to the collection of nasopharyngeal swabs and venous blood&#xD;
&#xD;
          6. The participant or legally authorized representative signed informed consent which&#xD;
             includes compliance with the requirements and restrictions listed in the informed&#xD;
             consent form (ICF) and in this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 &lt; 300, or a respiratory rate ≥30&#xD;
             per minute, or a heart rate ≥125 per minute&#xD;
&#xD;
          2. Has been admitted to a hospital prior to randomization, or is hospitalized (inpatient)&#xD;
             at randomization, due to COVID-19 or requires treatment with supplemental oxygen&#xD;
&#xD;
          3. Have known allergies to any of the components used in the formulation of the study&#xD;
             drug or placebo&#xD;
&#xD;
          4. Suspected or proven serious, active bacterial, fungal, viral, or other infection&#xD;
             (besides COVID-19) requiring systemic therapy and that in the opinion of the&#xD;
             investigator could constitute a risk to the subject or study assessments when taking&#xD;
             study drug or placebo&#xD;
&#xD;
          5. Have any co-morbidity anticipated to require surgery within &lt;7 days, or that is&#xD;
             considered life threatening within 30 days&#xD;
&#xD;
          6. Have received treatment with the anti-androgen agents or 5-alpha reductase inhibitors&#xD;
             within 3 months of the first dose&#xD;
&#xD;
          7. Prior, current, or planned future use of any of the following treatments at screening:&#xD;
             COVID-19 convalescent plasma, mAbs against SARS-CoV-2, IVIG (any indication), where&#xD;
             prior use is defined as the past 30 days or less than 5 half-lives of the&#xD;
             investigational product (which is longer) from screening&#xD;
&#xD;
          8. Are investigator site personnel directly affiliated with this study&#xD;
&#xD;
          9. Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30&#xD;
             days prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristhieni Rodrigues</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Paula</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Honglong Lu</last_name>
    <phone>86-010-85950839</phone>
    <email>hllu@kintor.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Santa Paula</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04556-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristhieni Rodrigues</last_name>
      <phone>+55 11 3040-8000</phone>
      <email>ombudsman@santapaula.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

